Related Experiment Videos
Hypercalcemia of malignancy: pathophysiology and implications for treatment
1Department of Medical Oncology, University of Texas, M.D. Anderson Cancer Center, Houston.
Oncology (Williston Park, N.Y.)
|January 1, 1993
Summary
Hypercalcemia of malignancy, a common cancer complication, requires understanding its causes and skeletal factors for effective treatment. Osteoclast inhibition therapies normalize calcium and may prevent bone metastases.
Area of Science:
- Oncology
- Endocrinology
- Metabolic Disorders
Background:
- Hypercalcemia of malignancy is a frequent and potentially fatal metabolic complication in cancer patients.
- It is commonly associated with solid tumors, particularly lung, head and neck, and breast carcinomas.
- Understanding the pathogenesis and skeletal factors is crucial for guiding therapeutic strategies.
Purpose of the Study:
- To review the pathogenesis of hypercalcemia of malignancy.
- To discuss the role of skeletal factors in its development.
- To outline therapeutic interventions and their impact on skeletal-related events.
Main Methods:
- Review of existing literature on hypercalcemia of malignancy.
- Analysis of therapeutic interventions targeting osteoclast activity.
- Examination of clinical trials investigating antiresorptive therapies.
Main Results:
- Osteoclast inhibition normalizes serum calcium by targeting the common pathway of hypercalcemia.
- Therapies like calcitonin, plicamycin, gallium nitrate, and bisphosphonates are effective.
- Antiresorptive therapies have spurred trials to prevent skeletal morbid events.
Conclusions:
- Effective management of hypercalcemia of malignancy involves understanding its mechanisms and employing osteoclast inhibitors.
- Antiresorptive therapies offer a dual benefit of managing hypercalcemia and potentially preventing skeletal complications.
- Further research and clinical trials are vital to optimize patient outcomes regarding bone metastases.